Vernal keratoconjunctivitis (VKC)
Ocular allergy · Ophthalmology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Chronic, bilateral, severe, typically spring-recurring ocular-surface allergic inflammation, usually in boys <10 years in warm/dry climates. Can cause corneal shield ulcers and vision loss, so it is not a benign conjunctivitis. DRAFT for clinician review.
Red flags
- Corneal shield ulcer
- Photophobia with decreased vision
- Severe eye pain
- Corneal opacity or plaque
- Patient using unsupervised topical steroids (IOP/glaucoma/cataract/infection risk)
Assessment
Differential diagnosis
- Atopic keratoconjunctivitis (perennial, adults, lower tarsus/inferior fornix)
- Seasonal/perennial allergic conjunctivitis
- Giant papillary conjunctivitis
- Infective conjunctivitis
- Toxic conjunctivitis
Investigations
- Clinical: ocular pruritus + giant 'cobblestone' papillae on the upper tarsal conjunctiva; Horner-Trantas dots in the limbal form
- Fluorescein staining to detect corneal shield ulcer / superficial keratopathy
- No routine labs; allergy testing only if immunotherapy considered (VKC unlikely if aeroallergen testing negative — reconsider other causes)
Management
- Basic eye care: avoid eye rubbing; avoid nonspecific triggers (wind, heat, sun, salt water); cool compresses; artificial tears
- Start topical dual-acting mast-cell stabiliser / H1 antihistamine
- Add oral antihistamine for moderate–severe disease not responding in 2–3 weeks
- Refractory disease → topical corticosteroid (ophthalmologist-supervised)
- Steroid-sparing topical cyclosporine/tacrolimus for frequent/prolonged steroid need
- Corneal shield ulcer → urgent ophthalmology
- Refer to allergist for immunotherapy if uncontrolled
Drugs & doses
Topical dual-acting mast-cell stabiliser + H1 antihistamine (first-line) — e.g. olopatadine, ketotifen fumarate, alcaftadine, azelastine, epinastine, bepotastine; standard doses, daily throughout the season; onset within minutes.
Topical mast-cell stabiliser (alternative) — cromolyn sodium, nedocromil, or lodoxamide; dosed 3–4×/day; slow onset (5–14 days), so start ~1 month before the season and not useful for acute symptoms.
Oral 2nd/3rd-generation H1 antihistamine (add-on for moderate–severe) — fexofenadine, loratadine, desloratadine, cetirizine, or levocetirizine; maximise dose; onset ½–2 h.
Topical corticosteroid for refractory disease (OPHTHALMOLOGIST only) — short high-dose burst (3–4 drops/day × 3–5 days, may repeat) or a taper over 1–3 weeks (twice daily ×1 wk, daily ×1 wk, alternate-day ×1 wk). Prefer 'soft' steroids: loteprednol etabonate 0.5/0.38/0.2%, prednisolone acetate 0.12%, or fluorometholone (lower IOP risk). Reserve prednisolone acetate 1% / dexamethasone 0.1% for severe bursts. NOT if corneal epithelium compromised; avoid >6 weeks.
Topical cyclosporine (steroid-sparing) — 0.1% one drop each eye 4×/day; may increase to 2% one drop each eye twice daily in severe/unresponsive disease. Alternative: topical tacrolimus (more burning).
Corneal shield ulcer — topical cyclosporine (NOT corticosteroid, which impairs re-epithelialisation) plus broad-spectrum antibiotic cover, e.g. moxifloxacin or gatifloxacin 4×/day; debridement / bandage contact lens / temporary tarsorrhaphy may be needed.
Systemic cyclosporine 2.5–5 mg/kg/day during the season — rarely needed, specialist use for severe steroid-dependent disease. Omalizumab reported effective in refractory cases.
Disposition
Mild–moderate: discharge on dual-acting drops with ophthalmology follow-up. Corneal shield ulcer, vision threat, or need for topical steroid: same-day/urgent ophthalmology referral.
Complications & pitfalls
- Corneal shield ulcer
- Corneal scarring and neovascularisation
- Amblyopia
- Steroid-induced glaucoma and cataract
- Secondary infective keratitis
Exam pearls
- Nearly all patients itch and have giant upper-tarsal cobblestone papillae
- Topical steroids are effective but MUST be ophthalmologist-monitored — risk of blindness if IOP unmonitored
- In known patients, start prophylaxis ~1 month before the usual season
- Usually outgrown by puberty
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.